Nu Skin Enterprises, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUS research report →
Range $11 – $11
Price Chart
About the company
Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageLOC Transformation age-defying lines, innovative devices like the ageLOC LumiSpa for comprehensive skin treatment and cleansing, and the ageLOC Boost, alongside various other cosmetic and personal care items.
- CEO
- Ryan S. Napierski
- IPO
- 1996
- Employees
- 2,800
- HQ
- Provo, UT, US
Get TickerSpark's AI analysis on NUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $223.09M
- P/E
- -1.03
- Fwd P/E
- 5.60
- PEG
- 0.00
- P/S
- 0.16
- P/B
- 0.41
- EV/EBITDA
- 7.56
- Div Yield
- 5.22%
- Gross Margin
- 69.19%
- Op Margin
- -0.62%
- Net Margin
- -15.73%
- ROE
- -29.42%
- ROIC
- -0.97%
Latest fiscal year · YoY change
- Revenue
- $1.49B-14.3%
- Gross Profit
- $1.03B-12.7%
- Op Income
- $90.88M
- Net Income
- $160.20M+209.3%
- EPS
- $3.25+210.2%
- OCF Growth
- -28.2%
- FCF Growth
- -34.4%
- 52W High
- $14.62
- 52W Low
- $4.49
- 50D MA
- $5.14
- 200D MA
- $7.75
- Beta
- 0.97
- RSI (14)
- 35
- Avg Volume
- 708.23K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nu Skin’s Q2 was pressured by lower profitability and a large non-cash impairment, but management leaned on Prysm iO rollout progress, cost actions, and updated guidance for a stronger second half.· August 10, 2026
- Q2 revenue was $320.1 million, with reported EPS of negative $5.14 and adjusted EPS in line with guidance.
- Prysm iO is still early, but device placements reached more than 39,000, up nearly 30% quarter over quarter, and scans hit 2.5 million, up 25%.
- India’s formal market launch was pushed to the first half of 2027 as management refines product quality, logistics, tech integration, and the business model.
- Gross margin was 68.2% versus 68.8% last year; core Nu Skin gross margin improved to 77.7%, up 20 basis points.
- The company updated full-year guidance to revenue of $1.28 billion to $1.35 billion and adjusted EPS of $0.70 to $0.90, with Q3 revenue guided to $310 million to $340 million.
Second-quarter revenue was $320.1 million, including an approximate 1% or $4 million foreign currency headwind. Reported EPS was negative $5.14, or positive $0.20 excluding non-cash accounting charges related to a goodwill impairment and deferred tax asset valuation allowance; adjusted EPS was in line with guidance. Gross margin was 68.2% versus 68.8% in the prior year, while core Nu Skin gross margin improved to 77.7% from 77.7%? actually up 20 basis points from the prior year. Adjusted operating margin was 6.1% versus 8% a year ago. Nu Skin recorded a $78.9 million non-cash goodwill impairment charge and a $167.5 million non-cash valuation allowance. For Q3, management expects revenue of $310 million to $340 million, with adjusted EPS of $0.10 to $0.20. For the full year, revenue is now expected to be $1.28 billion to $1.35 billion and adjusted EPS $0.70 to $0.90, with about a 1% foreign currency headwind and an effective tax rate of approximately 35% on adjusted results.
Ryan Napierski framed the quarter around three strategic priorities: expanding intelligent anti-aging with Prysm iO, reworking sales-force incentives, and building emerging markets. He emphasized that the company is learning how Prysm iO is actually being used, notably as a wellness consultation tool rather than purely an in-home placement device, and said those learnings are shaping the next phase of global rollout. His tone was constructive but realistic, repeatedly noting that recruiting and leadership development are still below what is needed for sustainable growth.
Chelsea Lantz said the quarter included $320.1 million of revenue, a 68.2% gross margin, and adjusted EPS that was in line with the company’s range. She highlighted a $15.9 million year-over-year decline in G&A, $10.6 million of operating cash flow, $189.6 million of cash and cash equivalents, and $213.7 million of total debt. She also detailed the non-cash charges: a $78.9 million goodwill impairment and a $167.5 million valuation allowance, and said the East-West operating model change should produce meaningful cost savings starting in the second half of this year, with larger benefits in 2027.
Analysts focused on India, Prysm iO’s impact on the sales force, and whether the company can hit its second-half guidance. Management said India’s delay reflects lessons on local manufacturing quality, logistics, systems integration, and tailoring the affiliate business model to local practices, and reiterated that formal opening is now targeted for the first half of 2027. On Prysm iO, Ryan said it is creating a learning curve for beauty-oriented affiliates but should create long-term synergy between beauty and wellness, while Q4 support should come from growing device interest, the Japan live event, and seasonal promotions.
The bull case is that Prysm iO adoption is accelerating from a small base, with placements and scans both rising quickly, and management believes the platform can deepen engagement and drive lifetime value. The company is also taking visible steps to improve margins and efficiency, while still investing in innovation and leadership development.
The bear case is that the core business still faces weak recruiting and leadership development, and management said those levels remain below what is needed for sustainable growth. The quarter also included large non-cash impairment and tax allowance charges, India’s launch was delayed to 2027, and the company expects cash-based transition costs of $5 million to $10 million as it restructures operations.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.1%
- Shares Outstanding
- 48.55M
- Float Shares
- 47.14M
of shares held by institutions
180 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.34M | ▲ 123.42K |
| Blackrock, Inc. | 4.32M | ▲ 24.61K |
| American Century Companies Inc | 2.30M | ▲ 280.11K |
| Vanguard Capital Management LLC | 2.05M | ▼ 13.71K |
| Acadian Asset Management LLC | 1.95M | ▲ 189.52K |
| Dimensional Fund Advisors LP | 1.80M | ▲ 61.56K |
| Prescott Group Capital Management, L.L.C. | 1.79M | 0 |
| Renaissance Technologies LLC | 1.61M | ▼ 92.80K |
| Charles Schwab Investment Management Inc | 1.45M | ▼ 690.36K |
| Sixth Street Partners Management Company, L.P. | 1.45M | ▲ 1.45M |
| Castleknight Management LP | 1.39M | ▲ 424.20K |
| Geode Capital Management, LLC | 1.27M | ▲ 81.03K |
Held by 146 ETFs
Biggest fund positions in NUS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 26 | WOODBURY EDWINA D | other | 19 |
| May 11, 26 | Nathanson Laura | sell | 2,676 |
| Mar 18, 26 | Lantz Chelsea K | other | 0 |
| Mar 11, 26 | WOODBURY EDWINA D | other | 14 |
| Mar 6, 26 | Keisel Justin S | other | 47,059 |
| Mar 6, 26 | Hatchett Steven Keith | other | 77,941 |
| Mar 6, 26 | Clark Chayce David | other | 138,971 |
| Mar 6, 26 | Thomas James D | other | 114,706 |
| Mar 6, 26 | NAPIERSKI RYAN S | other | 282,353 |
| Feb 26, 26 | Keisel Justin S | other | 13,687 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NUS coverage
Recent articles, reports, and earnings notes.
No research on NUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NUS report →Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2Q26
newsfilecorp.com · Aug 11
Nu Skin Enterprises Q2 Earnings Meet Estimates, Revenues Down Y/Y
zacks.com · Aug 11
Nu Skin Enterprises, Inc. (NUS) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 11
Nu Skin Enterprises Q2 Earnings Call Highlights
marketbeat.com · Aug 11
Nu Skin Enterprises (NUS) Matches Q2 Earnings Estimates
zacks.com · Aug 10
Nu Skin Enterprises Reports Second Quarter Results
businesswire.com · Aug 10
Nu Skin Enterprises Announces Quarterly Dividend
businesswire.com · Aug 10
Head-To-Head Analysis: BioHarvest Sciences (NASDAQ:BHST) versus Nu Skin Enterprises (NYSE:NUS)
defenseworld.net · Aug 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.